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Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a 
proteolytically-cleavable spacer sequence 
Received 27 August 1990 
Chimeric proteins composed of ricin toxin A chain (RTA) and staphylococoal protein A (PA) have been produced in E. coii. Construcb consisting 
of N-terminal RTA and C-terminal PA (RTA-PA) or N-terminal PA and C-terminal (PA-RTA) were capable of binding to immunoglobulin G 
(via PA) and of specitically depurinating 28 S ribosomal RNA (via RTA). Howevtx, neither fusion protein was cytotoxic to antigen-bearing target 
cells in the presence of an appropriate monoclonal antibody presumably because the RTA could not be released from the PA within the cytosol 
where the ribosomal substrate of RTA is located. The overcome this, a short ammo acid sequence from diphtheria toxin was engineered between 
the RTA and PA to produce a dis~~de-links loop containing a trypsin sensitive cleavage site. Cleavage of this fusion protein with trypsin converted 
the RTA-DT-PA to the two chain form consisting of RTA Iinked by a d&hide bond to PA. The cleaved fusion protein was highly toxic to Saudi 
cells coated with ~~-~~~oglob~in antibody suiting that the RTA could be released from the PA by reduction witbin the oytosol. 
Ricin A chain; Fusion protein; Protein A, ~oteol~ti~ily-cl~~ble sequexe 
1. INTRODUCTION 
The A chain of the potent cytotoxin ricin inhibits 
eukaryotic protein synthesis by catalytically inac- 
tivating the 60 S ribosomal subunit [l]. This results 
from the ~-~ycosidic leavage of a specific adenine 
residue from a highly conserved stem-loop structure of 
28 S ribosomal RNA [2,3]. Depurination at this site 
renders the 28 S rRNA unable to bind elongation fac- 
tors 141. In the holotoxin, the catalytic A chain is joined 
to a galactose-binding B chain by a single disulfide bond 
[l]. Cytotoxicity is mediated by the B chain which in- 
teracts with galactose residues of glycoproteins and 
glycolipids on the surface of target cells, and which is 
believed to play a role in transporting the A chain into 
the cytosol [l,J,B], Ricin A chain (RTA) is only 
catalytically active after release from the B chain (RTB) 
by reductive cleavage of the disulfide bond 171, 
Bacterial toxins such as diptheria toxin or 
P~~~o~~~~ exotoxin A contain 3 fuucti~n~ly 
distinct domains. These domains are responsible for 
target cell binding, translocation of the toxin across in- 
tercellular membranes and ADP-ribosylation of elonga- 
tion factor 2 (the step by which these bacterial toxins 
cause cell death), respectively [8,9]. Recombinant fu- 
sion proteins comprising fragments of these toxins and 
cell-binding ligands have been produced by expressing 
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chimeric genes in Escherichia co/i. The native cell bin- 
ding domain of the toxin has been replaced with, for ex- 
ample, interleukin-2 [lo], o-melanocyte stimulating 
hormone ill], transforming growth factor type CY [12] 
or antigen-binding antibody fragments [ 131. The 
resulting fusion proteins exert potent and specific 
cytotoxic effects upon target cells bearing the ap- 
propriate receptor or antigen, 
Similar types of fusion proteins containing plant tox- 
ins such as RTA have not been described. In ricin-based 
immunotoxins, the RTA is normally linked to an an- 
tibody via a disulfide bond [14]: RTA immunotoxins 
constructed with linkages lacking disulfide bonds have 
much weaker cytotoxic activity, probably because 
release of the RTA by reduction in the cytosol is re- 
quired for cytotoxicity. In the present report, we 
described the production of recombinant fusions bet- 
ween RTA and staphylococci protein A (PA). While 
both components of the fusions are biologically active, 
the chimeric proteins are not cytotoxic to antibody- 
coated cells. Cytotoxicity can be conferred, however, 
by joining the two components of the fusion via a 
~sulfide-liked peptide loop containing a trypsin- 
sensitive cleavage site. 
2. MATERIALS AND METHODS 
All plasmids were derivatives of pRIT5 (Pharmacia) which contain 
the S. fcl(reus PA coding sequence, including the 5’ signal sequeuce, 
downstream from the PA promoter. Plasmid pPA-RTA was produe- 
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ed by ligating an 879 bp BumHl fragment derived from pRIC [15], 
which contained the entire RTA coding sequence, in frame into the 
BamHl site of pRIT5. Plasmid pRTA-PA was produced by ligating 
a 836 bp end-filled Xhol-Kpnl fragment, which contained the entire 
RTA coding sequence, into a unique, end-filled Bell site in pRIT5. 
This results in the insertion of the RTA sequence into the PA sequence 
within the region encoding the first of the 5 antibody binding do- 
mains. The 5’ region of the 836 bp Xhol-Kpnl fragment was derived 
from the RTA Ml3 clone mutagenized to create the Xhol site at posi- 
tion - 15 [15], and the 3’ region was derived from the original 
preproricin cDNA [16]. A translational termination signal (contained 
in the Omega fragment [17]) was introduced after the PA coding se- 
quence in the EcoRI site of the pRIT5 multiple cloning region. 
The construction of plasmid pRTA-DT-PA involved 3 steps. First- 
ly, the omega region of pHP45Q [17] was isolated as a 2 kbp BomHl 
fragment and digested into two halves using Bell. A single half-omega 
fragment was isolated and ligated into the pRIT5 multiple cloning 
region which had been digested with EcoRI, end filled, and redigested 
with BamHl. The resulting construct provides translational stop 
codons in all reading frames after the PA coding sequence. The vector 
was further modified by deleting the Pstl and Sal1 multiple cloning 
sites. Secondly, a synthetic oligonucleotide containing a series of 
restriction sites (EcoRI, Xhol, EumHl, Bglll and Pstl) was ligated 
into the unique Bell site at position 66 in the PA coding sequence of 
pRIT5 generating pRIT5fI. Thirdly, a 90-mer oligonucleotide en- 
coding the diphtheria toxin (DT) trypsin sensitive site was ligated as 
a BumHl-Pstl fragment (Fig. la) into the new BumHl and Pstl sites 
of pRIT5Q. Encoded within this oligonucleotide are two cysteines 
which form a disulfide bond in DT and which, after normal pro- 
teolytic nicking of the bacterial toxin, covalently link the A and B 
fragments together [18]. Finally, the DNA encoding RTA was provid- 
ed as a 867 bp Xhol-BurnHl fragment and ligated into the new Xhol 
and BumHl sites of pRIT5B. The final construct encodes a 631 
residue protein fusion comprising a 36 residue signal peptide, 22 
residue of PA, 288 residues of RTA and linker, 34 residues of multiple 
cloning site remnants and DT loop and 25 1 residues of protein A. The 
fusion proteins encoded by the 3 expression vectors are illustrated 
schematicaly in Fig. lb. For expression, the recombinant plasmids 
were introduced into E. coli strain 71.18 by CaClz-mediated 
transformtion. Cultures (500 ml) were grown at 30°C in the presence 
of ampicillin (500 ml) to early stationary phase (As50 = 1 .O). E. co/i 
cells were harvested by centrifugation and resuspended in 10 ml of 10 
mM Tris-HCl, pH 7.4, 20% sucrose. The periplasmic fraction was 
isolated by osmotic shock as described [19]. 
2.2. Isolation of recombinant proteins 
The periplasmic fraction was applied to an IgG-Sepharose 6FF col- 
umn (1 x 6 cm, Pharmacia) that had been equilibrated in PBST (0.15 
M NaCl, 10 mM Na phosphate, pH 7.4, contasining 0.05vo Tween 
20). The column was washed with PBST until no protein was detected 
in the flow-through, and the bound material was then eluted with 0.1 
M glycine-HCl, pH 3.0. The eluted sample was neutralized im- 
mediately with 3 M Tris-HCl buffer pH 8.0 and dialysed overnight 
against PBS. 
2.3. Inhibition of protein synthesis 
The catalytic activity of RTA in the recombinant fusion proteins 
was determined by their ability to inhibit [‘4C]leucine incorporation 
into protein in a rabbit reticulocyte lysate [20]. A range of concentra- 
tions (0.1-1000 ng/ml) of recombinant proteins or purified native 
RTA were assayed for inhibition with respect o controls over a 5 min 
translational period at 28°C. Each concentration was assayed in 
triplicate. Evidence for RTA depurination of 28 S rRNA was obtained 
by aniline hydrolysis of total RNA extracted from the translational 
mixtures as described [21]. 
2.4. Trypsin cleuvuge of the DT loop 
Recombinant RTA-DT-PA was incubated with trypsin (1 *g/ml in 
50 mM Tris-HCl, pH 8.0, 1 mM EDTA) at 25’C for 30 s. Digestion 
was stopped by adding soybean trypsin inhibitor (5 fig/ml in 50 mM 
Tris-HCl, pH 8.0). 
(a) 
S'..GGA TCC TCT AGC CTC GAA GGT GGG TGC GCT 
Gly Ser SW Ser Leu Glu,Gly Gly Cys Ala 
GGT AAT AGA GTC AGA AGA'TCA GTC GGA AGC 
Gly Asn ArQ Vel ArQ APQ Ser Val Gly Ser 
AGC CTG TCT TGC GGT GOT CTC GAC CTG CAG..3' 
Ser Leu Ser Cys Gly Gly Leu Asp Leu Gln 
tb) 
pPA-RTA 
s PA RTA 
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Fig. 1. (a) Nucleotide and amino acid sequence of a 90-mer 
BumHl-Pstl fragment, which includes the trypsin cleavage site 
(arrowed) of the DT disulfide loop (underlined), and (b) schematic 
illustration of the fusion proteins encoded by the expression plasmids 
generated. 
2.5. Ricin B-chain (R TB)-mediated toxicity 
RTB-mediated cytotoxicity of RTA-DT-PA was measured by in- 
cubating RTA-DT-PA, without or after trypsin treatment, with RTB 
(Inland Laboratories, Dallas, TX) for 2 h at 8-10°C followed by 2 h 
at room temperature. Test mixtures were added in 25 ~1 volumes in 
phosphate buffered saline (PBS) to PBS-washed Vero cells, dispensed 
into 96 well microplates at 2 x 10“ cells per well. After 1 h at 37”C, 
100 p/well of DMEM was added and the plates were incubated for a 
further 20-24 h. Each well was then pulsed for 2 h with 1 &i 
[3sS]methionine in 50 $1 PBS, 0.5 M NaOH was added and the 
radioactivity was determined by scintillation counting. 
2.6. Cytotoxicity of RA T-PA to antibody-coo&d cells 
RTA-PA, PA-RTA and RTA-DT-PA fusions which had been 
treated or not treated with trypsin as above were mixed with 
equimolar quantities of rabbit anti-human Kappa light chain an- 
tibody (Sigma, Poole, UK). The mixtures were stored for 1 h at 4°C. 
Daudi lymphoblastoid cells, which express surface immunoglobulin 
(K light chain), were suspended at 4 x lo5 cells/ml in RPM1 1640 
Medium containing 0.5% w/v bovine serum albumin (BSA), insulin, 
transferrin and selenite supplement (Sigma), 200 U/ml penicillin and 
100 pg/ml streptomycin (serum-free medium). The cells were 
distributed in 100 d volumes into the wells of 96-well flat-bottomed 
microtitre plates and 100 jd of the test materials in serum-free medium 
was added. The plates were incubated for 24 h at 37°C in an at- 
mosphere of 5% CO2 in humidified air. After this time, 20 4 of foetal 
calf serum and I CCi [3H]leucine (Amersham Radiochemicals Ltd, 
UK) was added to each culture. The cultures were incubated for a fur- 
ther 24 h at 37°C. The cells were then harvested onto glass fibre discs 
using a Skatron automated cell harvester. The radioactivity on the 
disc was measured using a Packard Rae-beta liquid scintillation 
counter. The [‘Hlleucine incorporation of treated cells was compared 
with that of untreated cells to obtain the % inhibition of protein syn- 
thesis resulting from the treatment. In an alternative assay trypsin- 
treated or untreated RTA-DT-PA was mixed with WTl (a mouse 
monoclonal anti-CD7 IgGZa) or with HRS-1 (a mouse monoclonal 
IgG2a antibody of irrelevant specificity) before being incubated with 
CD7+ Jurkat cells which were processed as described above. The 
WTl antibody was a gift from Dr W. Tax, Nijmegen, The 
Netherlands, and the HRS-1 antibody was a gift from Dr M. Pfrennd- 
schuk, Cologne, FRG. 
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3. RESULTS AND DISCUSSION 12345670910 
3.1. Expression and purification of fusion protein 
E. coli cells transformed with each of the expression 
plasmids prepared here produced soluble, recombinant 
products of the expected molecular weight which were 
not formed in control, non-transformed cells. The PA 
component of the fusion proteins was functionally ac- 
tive, following the products to be purified from the 
periplasmic fraction in a single step by affinity 
chromatography on IgG-Sepharose (Fig. 2). 
Identification of the purified products was confirmed 
by Western blotting: all 3 fusion proteins crossreacted 
strongly with rabbit antibodies raised against recombi- 
nant ricin A chain [ 151. The purified products frequent- 
ly appeared as a doublet on gels (Pig. 2). We assume 
that the less mobile component has not had the PA 
signal sequence proteolytically removed while the more 
mobile one has. We have previously noted that the ex- 
tent to which a bacterial signal sequence preceding a 
recombinant protein targeted to the periplasmic space 
of E. coli is processed is host strain dependent [191. 
Fig. 3. Depurination of 28 S rRNA. Control ribosomes (lanes 1 and 
6) or ribosomes incubated with purified RTA (lines 2 and 7), PA-RTA 
(lanes 3 and 8), RTA-PA (lanes 4 and 8) and RTA-DT-PA (lanes 5 
and 10) were treated with aniline (lane 1 to 5) or untreated (lanes 6 to 
lo), and the RNA was extracted and fractionated. The arrow indicates 
the 390 ribonucleotide fragment released from RTA-modified 
ribosomes. 
3.2. Ribosome inactivation by the fusion proteins 
The purified fusion proteins were potent inhibitors of 
protein synthesis in rabbit reticulocyte lysates. RTA-PA 
and RTA-DT-PA had an I&, (the concentration re- 
quired for 50% inhibition of protein synthesis) of 
around 30 ng/ml, and were slightly more effective than 
PA-RTA (ICSO 90 ng/ml), but were an order of 
magnitude less active than purified RTA (I& 3 
ng/ml). The observed inhibition of protein synthesis 
resulted from the catalytic activity of the RTA compo- 
nent on its rRNA substrate. RTA depurinates 28 S 
rRNA at a specific site close to the 3 ’ end of the 
molecule. Depurination renders isolated rRNA suscep- 
tible to amine-catalysed hydrolysis of the 
phosphodiester bonds on either side of the modified 
site. This cleavage generated a small RNA fragment of 
about 390 ribonucleotides from reticulocyte 28 S rRNA 
which is therefore diagnostic of RTA ribosome inac- 
tivation. Reticulocyte ribosomes incubated with RTA- 
PA, PA-RTA and RTA-DT-PA all released the 
characteristic RNA fragment upon aniline treatment of 
the isolated rRNA (Fig. 3). 
123 
Mr 
Concentration (Ml 
Fig. 2. Affinity purification of recombinant fusion proteins. The 
periplasmic fraction from E. coli expressing PA-RTA (lane l), RTA- 
PA (lane 2) and RTA-DT-PA (lane 3) were passed down an IgG- 
Sepharose column. Bound material was eluted, separated by Na 
DodS041PAGE and stained with Coomassie blue. 
Fig. 4. (a) Inhibition of protein synthesis in Daudi cells. A range of 
concentrations of purified recombinant fusion proteins were mixed 
with equimolar quantities of rabbit anti-human Kappa light chain 
antibody and incubated with Daudi cells as described in the Materials 
and Methods before determining the ability of the cells to incorporate 
[‘?]leucine into protein. Cells were incubated with RTA-PA (A), 
PA-RTA (A), RTA-DT-PA without trypsin cleavage (0), RTA-DT- 
PA after trypsin cleavage (0). In other cultures cells were incubated 
with RTA (O), whole ricin (w), RTA-DT-PA without trypsin 
cleavage (0) and RTA-DT-PA after trypsin cleavage (+), all of which 
were not preincubated with rabbit anti-human Kappa light chain. (b) 
Inhibition of protein synthesis in Jurkat cells. RTA-DT-PA was 
mixed with equimolar quantities of mouse anti-CD7 or with control 
mouse IgG2a antibody and incubated with Jurkat cells: RTA-DT-PA 
with anti-CD7 (0) or with control antibody (A) without trypsin 
cleavage; RTA-DT-PA with anti-CD7 (0) or with control antibody 
(A) after trypsin cleavage. In other cultures, cells were incubated with 
RTA alone (0). Points represent he arithmetic means of triplicate 
determinations, the standard deviation of which were all less than rt 
10% of the mean values as plotted. 
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Pig. 5. Electrophoretic analysis of RTA-DA-PA before (lane 1) or 
after (lane 2 and 3) brief trypsin treatment in the presence (lanes I and 
3) or the absence (lane 2) of dithiothreitol. Tk arrows indicate the 
positions of the release RTA and PA bands. 
Recombinant RTA-FA and PA-RTA premixed with 
rabbit anti-human Kappa light chzlin (RAHk) were not 
cytotoxic to Daudi cells. Their ICSO values were greater 
than that of free RTA (10B7 M or greater) (Fig. 4a). In 
contrast, RTA-DT-PA premixed with RAHk was 
cytotoxic to Daudi cells (I&O = II x lo- i1 M), Trypsin 
treatment of RTA-DT-PA increased its toxicity approx- 
imately 4foid (XC50 = 2 x 10 - I1 M). Thus inclusion of 
the DT sequence and cleavage site in the recombinant 
fusion protein sig~fic~tly enhances cytotoxi&y. In 
the presence of antibody, the I&O for the trypsin- 
treated chime& protein approached that of whole ricin 
(6 x lo- ” M (Fig. 4a)f. The toxicity of RTA-DT-PA 
premixed with RAHk for Daudi cells was specific since 
RTA-DT-PA applied alone was several lOO-fold less 
toxic (I& = 3 x lo- ’ M for non-cleaved RTA-DT-PA 
and 6 x 10 - 9 M for cleaved RTA-DT-PA (Fig. 4a)) and 
RTA-DT-PA mixed with a mouse IgG2a antibody 
(which was also able to bind PA) was no more cytotoxic 
than RTA-DT-PA added alone (data not shown). 
In an aIternative cytoxicity assay RTA-DT-PA 
premixed with mouse anti-CD7 antibody specifically 
killed CD7+ Jurkat cells (Fig. 4b), although the poten- 
cy was low (ICSO = lo-’ M) and it was only lo-fold 
higher than that observed with a control mouse IgG2a 
antibody of irrelevant specificity (Fig. 4b). Trypsin 
cleavage did not increase the potency of RTA-DT-PA 
in the presence of anti-CD7 antibody suggesting, as did 
the experiment shown in Fig. 4a, that cellular pro- 
teoIyt.ic cleavage of RTA-DT-PA was occurring. 
The DT loop was specificahy susceptible to trypsin 
digestion. After digestion, the treated product ran with 
an apparent molecular weight indistinguishable from 
undigested product when electrophoresed under non- 
reducing conditions (Fig. 5, lanes 1 and 2). Under 
reducing conditions, two smaller bands were observed 
in the digested sample (Fig. 5, lane 3, arrowed) which 
were the expected apparent size for the RTA and PA 
components of the fusion protein, The bands released 
by limited trypsin digestion were difficult to visualize, 
but more prolonged trypsin treatment resulted in pro- 
teooiysis of the released RTA and PA polypeptides. The 
RTA band was positively identified by Western bbtting 
using anti-recombinant RTA antibodies, which also 
bound to a second band whose apparent size was that 
expected for PA (data not shown), 
Further evidence that proteolytic cleavage of RTA- 
DT-PA liberated a potentially t,oxic RTA fragment was 
obtslined using RTR-mediated cytotoxicity assays in 
which RTB reassociated with the liberated RTA to form 
ai ricin-like adduct. Recombinant RTA-DT-PA was not 
toxic to Vero ceils, even in the presence of 10m8 M 
purified RTR (TAble I). After trypsin treatment, 
however, RTA-DT-PA became potently cytotoxic in 
the presence of RTB (Table I), 
The fusion proteins RTA-PA and PA-RTA were not 
cytotoxic to target cells in the presence of an ap- 
propriate cell-reactive antibody. This accorded with the 
finding with chemically-linked antibody-RTA con- 
jugates that a disulfide linkage between the two protein 
components is necessary for cytotoxicity [22]. This sug- 
gested that the lack of toxicity of the RTA-PA and PA- 
Addition (% contro1) 
treatment 
None (control) No 100 
IQ-’ M RTB No 111 
1.5 x lo-’ M RTA-DT-PA No 
1,5 X lo- M RTA-DT-PA + lo-’ M RTB 
102 
NQ 
1.5 X IV9 M RTA-DT-PA + la-@ M RTB 
98 
Yr?S 
1.5 x 10Ia M RTA-DT-PA + IO-‘M RTB 
84 
Yes 24 
1.5 X 1O-7 M RTA-DT-PA + lo-’ M R’I’B Ye$ 8 
RTA-DT-PA, vvitb CK without trypsin treatment, was mixed w&b RTB befure incubation wiih Vera cells. The ability of’ the cells to incorporate 
f33S]me&kmine into protdn was determined. Each assay was performed in tripkate. 10-s M RTA pks 10-s M RTA gave 98% inhibition of 
prot& synthesis. 
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RTA was because the RTA could not be released from 
the PA by reduction within the cytosol in order to inac- 
tivate the cells’ ribosomes. We overcame this problem 
by inserting a cleavable linker, the DT loop, between 
the RTA and PA moieties. Trypsin cleavage of this 
linker resulted in RTB-mediated cytotoxicity to Vero 
cells (Table I) and antibody-mediated cytotoxicity to 
cells (Fig. 4). In the case of antibody-mediated cytotox- 
icity, prior cleavage with trypsin was not an absolute re- 
quirement; presumably proteases within the target cell 
can cleave the DT loop in the construct, as they do with 
non-nicked diphthe~a toxin itself 181. 
In an earlier study by Weaver et al. [23], functional 
recombinant PA-RTA was shown to be capable of bin- 
ding specifically to antigen-bearing target cells, There 
was, however, no indication that the fusion protein was 
cytotoxic. By contrast, disulfide-linked RTA and PA 
prepared by chemical means has been shown to be 
potently cytotoxic to antigen-bearing cells [24,25]. The 
present study demonstrates that recombinant RTA-PA 
fusions can also be cytotoxic provided that they contain 
an appropriate internal cleavage site which allows the 
generation of free RTA within the target cell. 
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